Drug Profile
Research programme: antibody-based cancer therapeutics - Kyowa Hakko
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Kyowa Hakko
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Japan (Parenteral, Injection)
- 17 Feb 2012 Preclinical development is ongoing in Japan
- 24 Oct 2008 Preclinical development is ongoing in Japan